Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
16 drugs in development
By Therapeutic Area
top 3
R&D Momentum
76/100
Pipeline Velocity
52/100
Trial Completion Rate
79/100
Pipeline Concentration
45/100
Pipeline Freshness
32/100
Strategic Signals
Activity
Last 14 days
Peking University Smart Monitoring and Responsive Technology for Early Childhood Health (PKU-SMART)
A Multicenter Clinical Study to Evaluate the Efficacy and Safety of Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression
A Multicenter, Parallel-Group, Community Cluster-Randomized Controlled Trial of a Hypertension Risk Model-Based Precision Intervention for Adults at High Risk of Hypertension in Shunyi District, Beijing, China
Peking University-Family Engaged, Enhanced Diet, for Kids (PKU-FeeD)
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
Effects and Multimodal EEG Mechanisms of an 8-week Mindfulness Intervention for Emotional Distress: A Randomized Controlled Trial
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)